AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
20/20 Biolabs statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Testing Laboratories companies for comparison
Valuation
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Market Cap | $3.32M | $73.61M |
| Enterprise Value | -$1.22M | $55.54M |
| PS Ratio | 1.63 | 3.25 |
| PB Ratio | 2.05 | 3.13 |
| P/TBV Ratio | 2.35 | 8.30 |
Enterprise value
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| EV / Sales | -0.60 | 2.79 |
Income (trailing twelve months)
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Revenue | $2.05M | $24.74M |
| Gross Profit | $604.54K | $19.54M |
| Operating Income | -$3.33M | -$55.64K |
| Net Income | -$3.74M | -$97.64K |
| EBITDA | -$3.27M | -$29.48K |
| EPS (Diluted) | -$0.76 | $0.00 |
Margins
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Gross Margin | 29.6% | 40.4% |
| Operating Margin | -162.9% | 0.94% |
| Profit Margin | -182.8% | 0.51% |
| EBITDA Margin | -159.8% | 3.48% |
Returns
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Return on Equity (ROE) | -379.1% | 0.45% |
| Return on Assets (ROA) | -61.1% | -3.47% |
| Return on Capital Employed (ROCE) | -93.3% | 2.03% |
Growth
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.7% | 4.26% |
Balance sheet
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.55M | $5.43M |
| Net Cash (Debt) | $4.55M | $17.62K |
| Net Cash Per Share | $0.36 | $0.00 |
| Equity (Book Value) | $1.62M | $10.50M |
| Book Value Per Share | $0.13 | $0.60 |
| Tangible Book Value | $1.41M | -$78.36K |
| Working Capital | $2.52M | $2.78M |
Financial position
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Current Ratio | 1.99 | 1.26 |
| Quick Ratio | 1.90 | 0.65 |
| Interest Coverage | -21.32 | -0.23 |
Cash flow (trailing twelve months)
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.92M | $8.04K |
Efficiency
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Asset Turnover | 0.33 | 0.83 |
| Inventory Turnover | 12.97 | 13.10 |
| Revenue Per Employee | $146.08K | $216.23K |
| Profits Per Employee | -$267.06K | -$1.99K |
| Employee Count | 14 | 115 |
Dividends and yields
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Earnings Yield | -112.5% | -1.29% |
Shares
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Shares Outstanding | 12,770,300 | 29,217,800 |
| Shares Change (YoY) | 2.70% | 0.84% |
| Shares Change (QoQ) | 17.3% | 0.00% |
| Float | 10,884,200 | 26,226,050 |
| Shares Held by Insiders | 14.8% | 4.85% |
| Shares Held by Institutions | 4.23% | 83.3% |
Scores
| Measure | 20/20 Biolabs | Industry median |
|---|---|---|
| Altman Z-Score | -8.74 | 2.64 |
| Piotroski F-Score | 5 | 5 |
| Beneish M-Score | -4.20 | -2.75 |
Calculated by StockData from 20/20 Biolabs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.